BRAF and neoplasm: In pooled multivariate analyses of PRIME and PEAK using the 45-month cut-off, panitumumab treatment again predicted long-term survival, along with low- and medium-risk Köhne score, BRAF WT status and left-sided primary tumour location (Table 4).